ADC Therapeutics ADCT is gearing up to announce its quarterly earnings on Thursday, 2024-11-07. Here's a quick overview of what investors should know before the release.
Analysts are estimating that ADC Therapeutics will report an earnings per share (EPS) of $-0.39.
The market awaits ADC Therapeutics's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
Past Earnings Performance
The company's EPS beat by $0.19 in the last quarter, leading to a 6.16% drop in the share price on the following day.
Here's a look at ADC Therapeutics's past performance and the resulting price change:
| Quarter | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| EPS Estimate | -0.44 | -0.56 | -0.50 | -0.63 |
| EPS Actual | -0.25 | -0.38 | -0.97 | -0.41 |
| Price Change % | -6.0% | 9.0% | -4.0% | -17.0% |
Tracking ADC Therapeutics's Stock Performance
Shares of ADC Therapeutics were trading at $3.05 as of November 05. Over the last 52-week period, shares are up 602.84%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.
To track all earnings releases for ADC Therapeutics visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
